The Emory Alzheimer's Disease Research Center (ADRC) coordinates growth and integrates basic research and clinical science activities relevant to Alzheimer's disease and other related neurodegenerative disorders. Our Team consists of a large multi-disciplinary group of faculty and staff committed to collaborations and the success of the ADRC. The ADRC Administrative Core plays the central role in coordinating interactions among the ADRC Cores and Research Projects and other centers and programs to leverage opportunities and achieve its goals. In our initial funding period we have established and documented standard operating procedures for each of the Cores, provided opportunities for regular communications and interactions, secured strong financial underpinnings with additional generous support from the institution and community, facilitated recruitment and development of junior faculty and minorities, and attracted new faculty to the field of AD research at Emory. The following specific aims will be pursued to achieve the Emory ADRC Administrative Core's mission: 1) To actively coordinate, integrate, and plan for all ADRC activities and research interactions and to oversee the progress to ensure optimal utilization, leveraging, and management of resources;2) To solicit, review, develop and implement Pilot and Research Projects;3) To enhance AD research, clinical care, and education by maximizing opportunities for interaction with other ADCs and AD investigators, as well as other local, regional, national, and international institutions, agencies, including NIA, and industries, and timely submission of data sets to the National Alzheimer's Coordinating Center;4) To cultivate an environment that promotes the highest standards for ethics in clinical care and research, and compliance with human subjects, animal welfare, fiscal policies, and scientific integrity. Through these aims we will continue building the relationships and connections necessary to advance efforts towards diagnosing and treating patients suffering from AD and other related neurodegnerative diseases.
The state of Georgia's population is aging rapidly and by 2030, one in five Georgians will be over 60. Given that advancing age is a primary risk factor in developing Alzheimer's disease, this population shift will pose a major public health problem in managing the consequences ofthe disease. The proposed work will provide the infrastructure necessary to support the efforts of the Emory ADRC to better understand the causes and hence accelerate improvements in care of individuals with Alzheimer's disease.
|Chalermpalanupap, Termpanit; Schroeder, Jason P; Rorabaugh, Jacki M et al. (2018) Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice. J Neurosci 38:74-92|
|Maezawa, Izumi; Nguyen, Hai M; Di Lucente, Jacopo et al. (2018) Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept. Brain 141:596-612|
|Bishof, Isaac; Dammer, Eric B; Duong, Duc M et al. (2018) RNA-binding proteins with basic-acidic dipeptide (BAD) domains self-assemble and aggregate in Alzheimer's disease. J Biol Chem 293:11047-11066|
|Peng, Katherine Y; Pérez-González, Rocío; Alldred, Melissa J et al. (2018) Apolipoprotein E4 genotype compromises brain exosome production. Brain :|
|Gangishetti, Umesh; Christina Howell, J; Perrin, Richard J et al. (2018) Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Alzheimers Res Ther 10:98|
|Zhang, Qi; Ma, Cheng; Gearing, Marla et al. (2018) Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer's disease. Acta Neuropathol Commun 6:19|
|Umoh, Mfon E; Dammer, Eric B; Dai, Jingting et al. (2018) A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med 10:48-62|
|Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169|
|Johnson, Erik C B; Dammer, Eric B; Duong, Duc M et al. (2018) Deep proteomic network analysis of Alzheimer's disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease. Mol Neurodegener 13:52|
|Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161|
Showing the most recent 10 out of 444 publications